Phase II/III pivotal study of Cannabidiol in Fragile-X-syndrome.
Phase of Trial: Phase II/III
Latest Information Update: 09 Jan 2018
At a glance
- Drugs Cannabidiol (Primary)
- Indications Fragile X syndrome
- Focus Therapeutic Use
- 09 Jan 2018 New trial record
- 03 Jan 2018 According to the Zynerba Pharmaceuticals media release, data read out from this study is expected in 2019.
- 03 Jan 2018 According to Zynerba Pharmaceuticals media release, the company expects to initiate this trial in mid of 2018.